Melanoma and IFN alpha: potential adjuvant therapy.

Area of Science:

• Oncology
• Dermatology
• Clinical Research

Background:

• Interferon alpha (IFNalpha) is a common adjuvant treatment for high-medium risk melanoma (MEL).
• Existing data on Overall Survival (OS) and disease-free survival (DFS) with IFNalpha treatment are conflicting.
• Predictors of patient outcomes in adjuvant IFNalpha therapy for melanoma require further investigation.

Purpose of the Study:

• To analyze outcomes in melanoma patients receiving adjuvant IFNalpha therapy.
• To identify predictors of Overall Survival (OS) and disease-free survival (DFS).
• To determine the optimal patient population for low-dose IFNalpha treatment.

Main Methods:

• Analysis of adjuvant Interferon alpha (IFNalpha) therapy in 140 melanoma (MEL) patients.
• Statistical analysis including Spearman's Coefficient test and Multiple Regression.
• Evaluation of patient outcomes based on Breslow thickness and ulceration status.

Main Results:

• Patients with Breslow thickness ≤2.00 mm had significantly longer DFS (p=0.01).
• DFS was significantly associated with Breslow thickness (p<0.001) and ulceration (p=0.03).
• Breslow thickness was the sole significant predictor in Multiple Regression analysis (p<0.001).
• Lower Breslow values (≤2.00 mm) and absence of ulceration correlated with better OS (p<0.0001 and p<0.004, respectively).

Conclusions:

• Low-dose IFNalpha is justified only for cutaneous melanoma with Breslow thickness ≤4.01 mm and no ulceration.
• For patients with Breslow thickness ≥4.01 mm, adjuvant low-dose IFNalpha may offer benefits outweighed by side effects.
• Treatment decisions should consider tumor characteristics and potential risks versus benefits of adjuvant IFNalpha therapy.